about
Gsh-1, an orphan Hox gene, is required for normal pituitary developmentRhinocerebral mucormycosis complicated by internal carotid artery thrombosis in a pediatric patient with type 1 diabetes mellitus: a case report and review of the literature.Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function.Advances in the recognition and treatment of endocrine complications in children with chronic illness.Hemoglobin A1c assay variations and implications for diabetes screening in obese youthApproach to the obese adolescent with new-onset diabetes.The metabolic syndrome and nonalcoholic fatty liver disease in childrenContinuous glucose monitoring and its relationship to hemoglobin A1c and oral glucose tolerance testing in obese and prediabetic youth.The eXtraordinarY Kids Clinic: an interdisciplinary model of care for children and adolescents with sex chromosome aneuploidy.Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY studyThe global spread of type 2 diabetes mellitus in children and adolescents.Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase.HbA1c After a Short Period of Monotherapy With Metformin Identifies Durable Glycemic Control Among Adolescents With Type 2 Diabetes.Addition of metformin to a lifestyle modification program in adolescents with insulin resistancePresence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease.Psychological functioning in adolescents with obesity co-morbidities.Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes.Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacityUpdate on nonautoimmune diabetes in children.Clinical trials in youth-onset type 2 diabetes: needs, barriers, and options.Insulin Resistance of Puberty.Advances in the Interdisciplinary Care of Children with Klinefelter Syndrome.Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience.Considerations regarding the diagnosis and treatment of childhood type 2 diabetes.Testosterone, obesity and insulin resistance in young males: evidence for an association between gonadal dysfunction and insulin resistance during puberty.The relationship between thyroid dose and diagnosis of primary hypothyroidism in pediatric brain tumor patients receiving craniospinal irradiation.Gonadal function is associated with cardiometabolic health in pre-pubertal boys with Klinefelter syndrome.Food and levothyroxine administration in infants and children.Type 2 diabetes in children and adolescents.Editorial: School-based intervention to reduce obesity and diabetes risks: small steps for a big problem.Antagonism of endogenous growth hormone-releasing hormone (GHRH) leads to reduced proliferation and apoptosis in MDA231 breast cancer cells.Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions.Oral glucose tolerance testing in asymptomatic obese children: more questions than answers.A boost to the study of insulin secretion in children and adolescents.Insulin resistance, obesity, and related disorders among black adolescents.Congenital hypothyroidism and the second newborn metabolic screening in Colorado, USA.Effects of Oxandrolone on Cardiometabolic Health in Boys With Klinefelter Syndrome: A Randomized Controlled Trial.Barriers to the treatment of adolescent type 2 diabetes--a survey of provider perceptions.Growth hormone-releasing hormone neurons in the arcuate nucleus express both Sst1 and Sst2 somatostatin receptor genes.
P50
Q28506940-287BB424-C669-476A-BD49-2069424117C4Q31028382-65F4DFE1-111A-4FCB-91AE-1CE002DF2181Q33736145-9BF0BF93-65F9-4600-BD46-80306CE6214BQ33823102-4B8577F4-ADEF-4182-9AA2-60EF680E77B4Q34203076-C7890B10-83D9-4E97-A3A6-8CE8F5DAE88EQ34395471-979F277C-901B-465A-AF1B-4992FFB774CEQ34778237-BE5D1BC6-0176-4B7D-A35A-46A85CDF5724Q35096837-9568213B-7CF5-4554-88BA-CC4318E48325Q35887591-7A6CCDC0-5897-45D9-95A8-BDFA95D4F452Q35963437-652085FF-3504-4FEA-996C-955F57C86FB9Q36116070-2660DE91-03FC-4720-B3CC-DDC73BA81578Q36180447-AC622C1C-1CE1-46B8-A80F-7526FA180F82Q36311680-CCBAF389-69F2-4D2A-8718-916DF1F06B9DQ36980289-1CD1F2FF-CAEC-4F76-ADDE-8788476BFE07Q37012994-B36A83F7-06E9-45D9-8317-C6CD4D60477AQ37058227-E6BDB4E4-20AB-41CE-AECD-B7CABC1537ACQ37363550-76ACE80D-CC33-4BA2-991A-B8D9D2008FA3Q37379571-CE69150C-5DF7-4BB4-BFC9-CFC472A2AC6AQ37543775-189FA8A9-0A8C-4C59-B55D-8B6A7D948943Q38380568-BCAC1611-4200-44A8-AFBF-B303F1BC28C6Q38834653-3DC7B7D5-12E2-4596-ACA3-7AB92255ADFFQ38900036-119BE418-A5C0-4C3C-98C6-A8E501B4BFF3Q39858231-4AF87E85-CEFC-4373-A772-9761B3C45F34Q40628070-422E0B49-F662-4EF7-8A78-39EF1AAA0FA0Q42171293-AD857684-D8BF-4A3E-A898-A44990E092A5Q42731377-B8F85C51-3267-4B01-B786-E34501F54090Q42911273-394AAE3F-3C47-4B30-8C86-B6275FDCF718Q43007144-A6278498-B5E9-46A3-BB70-049FB3A19630Q43024001-7CC5321B-1459-406D-9992-C5BF7B23EFD1Q43276515-13D589E0-E90B-402A-8DA6-94C2F5EA3C20Q43628399-4E94DD2B-49FB-42E5-871C-6B4082A8AD3BQ44093176-DAEBCA8B-4C7F-4E5B-AD22-76512E8C5887Q44414932-5792F4B5-CAEF-4C2E-9EAD-7BB33A64A729Q46262223-BA296417-B1C8-4260-9699-EFCB4A0A9522Q46645947-DFD14F7E-2DC5-4A87-BDE7-7710485A965EQ46946681-825BC247-D402-4767-83D1-4A3683CEB66FQ46969946-4A71089E-72C4-435D-9331-6CA40425A6DBQ47153898-99DF3EA4-F8E1-4240-9D53-70033208487AQ47366149-27BD2D01-AAEE-41CE-B793-F72701599928Q48517704-61CEDB7D-D5D7-4D1E-89E3-BC9CCC03CE10
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Philip Zeitler
@ast
Philip Zeitler
@en
Philip Zeitler
@es
Philip Zeitler
@nl
Philip Zeitler
@sl
type
label
Philip Zeitler
@ast
Philip Zeitler
@en
Philip Zeitler
@es
Philip Zeitler
@nl
Philip Zeitler
@sl
prefLabel
Philip Zeitler
@ast
Philip Zeitler
@en
Philip Zeitler
@es
Philip Zeitler
@nl
Philip Zeitler
@sl
P1006
P214
P1006
P106
P21
P214
P31
P496
0000-0001-5756-7858
P735
P7859
lccn-n88665121